Clinical tumor lysis syndrome associated with elranatamab in relapsed multiple myeloma

20260 citationsJournal Articlediamond Open Access

Authors

TLS is an uncommon complication of MM treatment and could be triggered by bispecific antibodies.

Good health and well-being

Published in: Revista de la Facultad de Ciencias Médicas de Córdoba

Volume 83, Issue 1, pp. e49234-e49234

Field-Weighted Citation Impact: 0.00